Sign inJoin waitlistJoin the waitlist

Nataliya Uboha

Internal Medicine Residency · University of Wisconsin Hospitals and Clinics

Credentials: · · · ·

History

Internal Medicine
University of Wisconsin Hospitals and Clinics
2024–Present
Hematology and Medical Oncology
Yale-New Haven Hospital
2027–2030
Yale Univ Sch of Med
2003–2007

Research

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy:…
The Lancet Oncology · 2022 · 226 citations
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025 · 179 citations
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Cancer Discovery · 2024 · 117 citations

Dustin Deming
14 papers
Sam Lubner
12 papers · 5 as a resident
Noelle LoConte
10 papers · 5 as a resident
Jeremy Kratz
9 papers · 7 as a resident
Michael Bassetti
8 papers · 1 as a resident
Kristina Matkowskyj
6 papers
Monica Patel
6 papers · 1 as a fellow
SK
Samuel Klempner
6 papers
Dan Mulkerin
5 papers
Daniel Abbott
5 papers
Sharon Weber
5 papers
Howard Hochster
4 papers

Grants

UW Comprehensive Cancer Center Support
National Cancer Institute · P30
Project lead · $730.9K · University of Wisconsin-Madison
1997–2028

Clinical trials

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Principal investigator · Active not recruiting · Phase 2
Nataliya Uboha
2024–2027
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
Principal investigator · Recruiting · Phase 2
University of Wisconsin, Madison
2020–2028
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Principal investigator · Active not recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
2020–2028
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Principal investigator · Terminated · Phase 2
Nataliya Uboha
2019–2020